Cancer treatment methods

Details Cancer treatment methods Cancer treatment methods

2011-03-15

2011-03-15

Peselev, Elli (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C514S178000, C514S182000, C552S502000

Reexamination Certificate

active

07906497

ABSTRACT:
The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications.

REFERENCES:
patent: 2251939 (1941-08-01), Kathol
patent: 2266778 (1941-12-01), Logemann et al.
patent: 2267257 (1941-12-01), Ruzicka
patent: 2308833 (1943-01-01), Ruzicka et al.
patent: 2332486 (1943-10-01), Hildebrandt et al.
patent: 2868811 (1959-01-01), Clinton et al.
patent: 3210249 (1965-10-01), Beerstecher et al.
patent: 3654320 (1972-04-01), Ayer et al.
patent: 4898694 (1990-02-01), Schwartz et al.
patent: 5387583 (1995-02-01), Loria
patent: 5461042 (1995-10-01), Loria
patent: 5567830 (1996-10-01), Upasani
patent: 5593981 (1997-01-01), Labrie
patent: 5859000 (1999-01-01), Dowell et al.
patent: 5912240 (1999-06-01), Loria
patent: 5925630 (1999-07-01), Upasani et al.
patent: 6667299 (2003-12-01), Ahlem et al.
patent: 7462610 (2008-12-01), Lardy et al.
patent: 7524835 (2009-04-01), Frincke
patent: 7691835 (2010-04-01), Frincke
patent: 7696189 (2010-04-01), Frincke
patent: 2006/0079492 (2006-04-01), Ahlem et al.
patent: 2006/0088473 (2006-04-01), Dowding et al.
patent: 2007/0077201 (2007-04-01), Reading et al.
patent: 2007/0129282 (2007-06-01), Ahlem et al.
patent: 2008/0021006 (2008-01-01), Lardy et al.
patent: 2008/0176823 (2008-07-01), Lardy et al.
patent: WO 97/37662 (1997-10-01), None
patent: WO 99/63973 (1999-12-01), None
Chang et al, Suppression of Δ5-androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells,Proc. Natl. Acad. Sci. USA., 96(20):11173-11177, 1999.
Clinton et al, Esters of 17α-Ethinylandrostane-3β,17β-diol and 17α-ethinylandrost-5-ene-3β,17β-diol,J. Org. Chem., 22:473-475 1957.
Gatto et al, Dehydroepiandrosterone inhibits the growth of DMBA-induced rat mammary carcinoma via the androgen receptorOncol. Rep., 5(1):241-243, 1998.
Hackenberg et al, Estrogen and androgen receptor mediated stimulation and inhibition of proliferation by androst-5-ene-3β,17β-diol in human mammary cancer cells,J. Steroid Biochem. Molec. Biol., 46(5):597-603 1993.
Mahendroo et al, 5α-Reduced Androgens Play a Key Role in Murine Parturition,Mol. Endo., 10(4):380-392, 1996.
Marwah et al, C19-Steroids as androgen receptor modulators: Design, discovery, and structure-activity relationship of new steroidal androgen receptor antagonists,Bioorg. Med. Chem., 14:5933-5947 2006.
Miyamoto et al, Δ5-Androstenediol is a natural hormone with androgenic activity in human prostate cancer cells,Proc. Natl. Acad. Sci. U. S A. 95(19):11083-11088, 1998.
Moore et al. Concentration of dihydrotestosterone and 3α-androstanediol in naturally occurring and androgen-induced prostatic hyperplasia in the dogJ. Clin. Invest., 64:1003-1010, 1979.
Segaloff et al, Hormonal therapy in cancer of the breast II. Effect of methylandrostenediol on clinical course and hormonal excretion,Cancer, 5(2):271-74, 1952.
Segaloff et al, Hormonal therapy in cancer of the breast IV. Effect of androstenediol on clinical course and hormonal excretion,Cancer, 5(6):1179-1181, 1952.
Segaloff et al, Testosterone and miscellaneous steroids in the treatment of advanced mammary cancer,Cancer, 10(4):808-812 1957.

Affiliated with

Also associated with

Rating

Cancer treatment methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cancer treatment methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer treatment methods will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2639973